Development of High specific reagents for BNCT

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461895
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Fukushima Medical University
• Principal Investigator: Tominaga Hideyuki 福島県立医科大学, 公私立大学の部局等, 准教授 (00393348)
• Research Collaborator: KANAI Yoshikatsu 大阪大学, 医学系研究科・薬理学, 教授
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: ホウ素 / BNCT / アミノ酸 / LAT1 / 腫瘍特異的

Outline of Final Research Achievements

Representative isoforms of L-type neutral amino acid transporter include LAT1 and LAT2, LAT1 is specific to cancer cells, and LAT2 is distributed in normal cells. There is also a difference in the transport amino acid substrate selectivity of both, while LAT 2 transports all neutral amino acids, whereas LAT 1 mainly transports large neutral amino acids (leucine, tyrosine, etc.).
Alpha-methyl tyrosine developed by us is an amino acid derivative with high selectivity for LAT1. I reported this usefulness during the research period. However, as a drug for boron neutron capture therapy, it was not possible to improve water solubility, and due to the introduction of a plurality of boron, drug development such as a decrease in selectivity of LAT 1 per se was not realized.

Free Research Field

放射線化学